UCB Acquires Engage Therapeutics: Staccato(R) Alprazolam - A potential Solution for Acute On-demand Seizure Management for People Living With Epilepsy

Underlines UCB's leadership in epilepsy by adding Staccato® Alprazolam, a drug-device-combination with the potential to be the first on-demand, single-use treatment to rapidly terminate an active epileptic seizure Staccato® Alprazolam could be a... Devices, Drug Delivery, Neurology, Mergers & Acquisitions UCB , Engage Therapeutics, Staccato Alprazolam, epileptic seizure
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news